Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 28, 2022

SELL
$2.6 - $6.14 $2 - $6
-1 Closed
0 $0
Q4 2021

Jan 24, 2022

SELL
$8.55 - $111.89 $290 - $3,804
-34 Reduced 97.14%
1 $0
Q1 2021

Apr 12, 2021

BUY
$109.73 - $153.66 $3,840 - $5,378
35 New
35 $4,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $98.3M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Private Capital Group, LLC Portfolio

Follow Private Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Capital Group, LLC with notifications on news.